A new hydrogel to improve cancer immunotherapy
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local Immunotherapy
This study is looking at a new gel called SynerGel that helps make cancer immunotherapy work better by delivering treatments right to the tumor, which could lead to fewer side effects and better results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11064837 on NIH RePORTER |
What this research studies
This research investigates a novel hydrogel called SynerGel, designed to enhance the effectiveness of cancer immunotherapy by modifying the tumor microenvironment. By delivering immunotherapeutics directly to the tumor site, it aims to increase the concentration of these treatments while reducing systemic side effects. The hydrogel works by depleting suppressive immune cells and releasing various factors in a controlled manner, potentially leading to better patient outcomes. Patients may benefit from a more targeted approach to immunotherapy that minimizes adverse effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer who are undergoing immunotherapy.
Not a fit: Patients who do not have cancer or those whose cancer is not responsive to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments for patients.
How similar studies have performed: Other research has shown promise in using biomaterials for cancer immunotherapy, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Young, Simon — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Young, Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.